Navigation Links
Haymarket Adds Two Cancer Journals to Its Family of Clinical Publications
Date:3/21/2008

NEW YORK, March 21 /PRNewswire/ -- Haymarket Media Inc. is now the publisher of two leading journals for cancer clinicians, The American Journal of Hematology/Oncology and Oncology Nursing News, under an agreement announced today. Both titles were previously published by U.S. HealthCare Communications, of Highland Park, NJ.

"We are very pleased to add a strong oncology presence to the Haymarket clinical family," said Lee Maniscalco, CEO. "The practical, clinical guidance these publications offer to their readers, and the wide variety of Continuing Education opportunities they provide throughout the year -- within the journals themselves, in special supplements, and in Web-based initiatives -- make this a perfect fit for Haymarket. The addition of these two publications is entirely consistent with our goal of expanding and enhancing learning opportunities for practicing cancer clinicians nationwide."

The American Journal of Hematology/Oncology (AJHO) reaches oncologists, hematologists, and other cancer clinicians nationwide. Each monthly issue offers concise summaries and expert commentaries on the peer-reviewed scientific literature and conference proceedings, so that the latest research findings can be applied in day-to-day patient care. The editorial board is headed by Lawrence N. Shulman, MD, Chief Medical Officer, Dana Farber Cancer Institute, and Associate Professor of Medicine, Harvard Medical School, Boston; and Douglas J. Schwartzentruber, MD, Medical Director of the Goshen Center for Cancer Care, Goshen, Indiana. Marcus E. Randall, MD, Professor and Chair of Radiation Medicine at the University of Kentucky School of Medicine, Lexington, serves AJHO as Associate Editor for Radiation Oncology. Each issue of the journal offers Continuing Medical Education accredited by Harvard Medical School.

Oncology Nursing News (ONN) provides late-breaking clinical news and practical guidance to nurses, nurse practitioners, and physician assistants across all settings of cancer care and supportive services. ONN offers coverage from the most significant oncology meetings throughout the year, news of clinical relevance from the peer-reviewed literature, and how-to advice based on the clinical and management experiences of leading oncology nurses. The Editor in Chief is Regina Cunningham, PhD, RN, AOCN, Chief Nursing Officer of The Cancer Institute of New Jersey, UMDNJ-Robert Wood Johnson Medical School, New Brunswick.

"We look forward to working with the staffs of these publications and the outstanding experts who serve on their editorial boards to bring the very best and latest information to the dedicated clinicians who care for cancer patients," said Maniscalco.

Haymarket Media Inc., based in New York City, publishes a variety of clinical journals and drug information digests for health professionals, including Monthly Prescribing Reference, Renal & Urology News, Cortlandt Forum (for primary-care physicians), The Clinical Advisor (for nurse practitioners and physician assistants), The Journal of the American Academy of Physician Assistants, McKnight's Long-Term Care News, and Assisted Living.


'/>"/>
SOURCE Haymarket Media Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... TX (PRWEB) , ... September 20, 2017 , ... ... date of the much-anticipated fall event , Look Awesome This Autumn with ... personalized consultations, special pricing and refreshments. , Mirror Mirror Beauty Boutique is ...
(Date:9/20/2017)... ... September 20, 2017 , ... Announced that Clear Global ... support services market) has entered into an agreement on September 1, 2017 with ... PGSD is the first private Dental School to launch an online, accredited Post ...
(Date:9/20/2017)... ... , ... Compliancy Group is proud to announce that its ... another long-time client pass their Department of Health and Human Services (HHS) Office ... to the help of the Compliancy Group's Audit Response Program™, not a single ...
(Date:9/20/2017)... ... September 20, 2017 , ... In just a short ... has already been receiving positive feedback from customers trying the product for the first ... Daily Brain Booster was developed by neurosurgeon Shawn Moore, MD, for everyone from athletes ...
(Date:9/20/2017)... ... September 20, 2017 , ... Five consumer packaged goods ... market impact in 27 different categories. Nopavera Plus was named to the ... be announced at SupplySide West 2017 during presentations at SupplySide Central on Sept. 27 ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... 2017  For nearly two decades, New Life Agency has been committed ... industry. Today, New Life Agency announces a powerful three-way partnership designed to ... ... ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
Breaking Medicine Technology: